Evidence map›Paper›PMID 33923858›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH

Jiqing Ye, Lin Lin, Jinyi Xu, Paul Kay-Sheung Chan, Xiao Yang, Cong Ma

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Ligand-Based Drug Design of Novel Antimicrobials againstInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiqing YeState Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.ORCID 0000-0003-2461-4325
Lin LinDepartment of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
Jinyi XuState Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China.
Paul Kay-Sheung ChanDepartment of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
Xiao YangDepartment of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
Cong MaState Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.ORCID 0000-0001-9245-0356

Funding

Chinese University of Hong Kong Faculty Innovation Award No. FIA2018/A/03Hong Kong Polytechnic University 1-ZVPSHong Kong Polytechnic University G-YBYYHong Kong Polytechnic University Large equipment fundHong Kong Polytechnic University State Key Laboratory of Chemical Biology and Drug DiscoveryResearch Grants Council C5008-19GResearch Grants Council CUHK 141079/19MResearch Grants Council PolyU 151000/19M
6 · The paper itself

Abstract

Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate (

Indexed as

150-cavityinfluenza virusneuraminidase inhibitoroseltamivir derivativespyrazole

Identifiers

PMID33923858
PMCPMC8073777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.